Detailed Information

Cited 6 time in webofscience Cited 7 time in scopus
Metadata Downloads

Satisfaction of patients and caregivers with long-acting injectable risperidone and oral atypical antipsychotics

Authors
Han, CSLee, BHKim, YKLee, HJKim, SHKim, LLee, MSJoe, SHHam, BJJung, IK
Issue Date
2005
Publisher
LIBRAPHARM
Keywords
atypical; depot; long-acting injectable risperidone; satisfaction
Citation
PRIMARY CARE & COMMUNITY PSYCHIATRY, v.10, no.3, pp 119 - 124
Pages
6
Indexed
SCIE
SCOPUS
Journal Title
PRIMARY CARE & COMMUNITY PSYCHIATRY
Volume
10
Number
3
Start Page
119
End Page
124
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/20169
DOI
10.1185/135525706X75267
ISSN
1746-8841
Abstract
Background.-The satisfaction of schizophrenia patients with their treatment can strongly influence treatment adherence and subsequent long-term outcome. Atypical antipsychotics reportedly have greater adherence rates, owing to a lower incidence of side effects and higher levels of patient satisfaction and acceptability. However, patient satisfaction with long-acting injectable atypical antipsychotics has not been compared with that of oral atypical antipsychotics. Objective: The objective of the study was to identify differences in patient and caregiver satisfaction between long-acting injectable risperidone and oral atypical antipsychotics. Research design and methods: Forty-seven patients with schizophrenia, who were currently receiving treatment with long-acting injectable risperidone and their caregivers were surveyed using a semi-structured questionnaire that addressed their drug satisfaction and acceptability. Sixty-two patients currently taking oral atypical antipsychotics and their caregivers were surveyed for comparison. In the questionnaire, subjects were asked to indicate their satisfaction level on a 10-point visual analogue scale (VAS). Items to identify discomfort and side effects experienced were also included. Results: The VAS satisfaction score was significantly higher for patients receiving long-acting injectable risperidone than for those taking oral atypical antipsychotics (7.53 vs 6.87, P < 0.05). The overall VAS score was significantly higher for caregivers of both groups of patients than for the patients themselves (8.04 vs 7.16, P < 0.000). Conclusion: A new drug delivery system using long-acting injectable risperidone may offer better adherence in schizophrenia treatment, owing to higher levels of patient and caregiver satisfaction, and thereby result in improved treatment outcomes. Further studies in a strictly controlled setting are strongly needed because that present study was not strictly controlled and the duration of treatment of the injection group was relatively short.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Psychiatry > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Joe, Sook Haeng photo

Joe, Sook Haeng
Guro Hospital (Department of Psychiatry, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE